Project description
A new biological drug against autoimmune conditions
Rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) are chronic and debilitating conditions that respectively affect around 1 % of the adult population and thousands of children worldwide. Current therapeutics work by suppressing the patient immune system and fail in nearly 30 % of patients. The scope of the EU-funded Notid project is to bring a novel protein-targeting drug as a treatment of chronic inflammatory diseases. Preliminary results are promising and indicate that the drug can be used to treat an array of autoimmune and autoinflammatory conditions, improving the quality of life of patients.
Objective
Lipum AB has discovered a novel target protein for treatment of chronic inflammatory diseases. We are now developing a biological drug that will inhibit the target molecule. We propose an entirely new therapeutic mode of action as an alternative to current therapeutics that do not provide adequate response in as much as 1/3 of patients. Our research and preclinical results indicate that our approach can be applied for treatment of an array of autoimmune and autoinflammatory conditions, and that the suppression of the patient immune system can be avoided, which otherwise is a common negative side effect limiting treatment options. Currently, Lipum is focused on delivering a humanised candidate drug. Our aim is to to reach a drug development phase where toxicology and safety tests can be started and establish collaborations needed to proceed with the clinical studies. Within the lifecycle of this project, Lipum will focus on providing preclinical evidence, securing IP and reaching out to partners interested in exploitation of our approach for the treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis. These are chronic and debilitating conditions that affect around 1% of adult population (RA) or thousands of children (JIA) worldwide. Both RA and JIA are important cause of disability and generate high costs of healthcare and lost productivityLipum AB is a Swedish SME founded in 2010 with the aim to bring to the market a new biological drug for chronic inflammatory diseases. An effective and safe alternative has been long expected by the millions of patients that struggle with chronic and debilitating conditions like Rheumatoid arthritis (RA), Psoriatic Arthritis (PsA), or Inflammatory Bowel Disease (IBD), and by the rheumatology opinion leaders that have been highlighting the unmet clinical need in this domain. Apart from the patients’ well-being and quality of life, chronic inflammatory diseases incur high social costs of healthcare and lost productivity.
Fields of science
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesclinical medicinerheumatology
- medical and health scienceshealth sciencesinflammatory diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesclinical medicinegastroenterologyinflammatory bowel disease
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
Programme(s)
Funding Scheme
SME-2 - SME instrument phase 2Coordinator
907 36 Umea
Sweden
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.